CRDF Q1 2023 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$83,000+12.2% YoY

Gross Profit

$83,000100.0% margin

Operating Income

-$12M-14520.5% margin

Net Income

-$11M-13521.7% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

-35.2%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$107M

Total Liabilities

$10M

Stockholders' Equity

$97M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83,000	$74,000	+12.2%
Gross Profit	$83,000	$74,000	+12.2%
Operating Income	-$12M	-$11M	-8.8%
Net Income	-$11M	-$11M	-2.1%